# Envoy Medical, Inc.: financial statements, quarterly

COCH · Nasdaq · CIK 1840877 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/coch.md) · [Financials](/companies/coch/financials.md) · [Filings](/companies/coch/filings.md) · [Insiders](/companies/coch/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/coch/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [80.0](/filings/0001213900-24-097861.md) | [95.0 d](/filings/0001013762-25-004299.md) | [59.0](/filings/0001213900-25-038468.md) | [68.0](/filings/0001213900-25-069663.md) | [56.0](/filings/0001213900-25-107902.md) | [42.0 d](/filings/0001213900-26-032683.md) | [46.0](/filings/0001213900-26-054209.md) | [78.0](/filings/0001213900-26-086974.md) | [42.0](/filings/0001213900-25-107902.md) | [75.0 d](/filings/0001213900-26-032683.md) | [39.0](/filings/0001213900-26-054209.md) | [51.0](/filings/0001213900-26-086974.md) |
| Cost of revenue | $k | [189](/filings/0001213900-24-097861.md) | [234 d](/filings/0001013762-25-004299.md) | [153](/filings/0001213900-25-038468.md) | [245](/filings/0001213900-25-069663.md) | [187](/filings/0001213900-25-107902.md) | [157 d](/filings/0001013762-25-004299.md) | [226](/filings/0001213900-26-054209.md) | [234](/filings/0001213900-26-086974.md) | [203](/filings/0001213900-25-107902.md) | [211 d](/filings/0001213900-26-032683.md) | [313](/filings/0001213900-26-054209.md) | [278](/filings/0001213900-26-086974.md) |
| Research and development | $k | [1,850](/filings/0001213900-24-097861.md) | [3,055 d](/filings/0001013762-25-004299.md) | [2,360](/filings/0001213900-25-038468.md) | [2,591](/filings/0001213900-25-069663.md) | [2,757](/filings/0001213900-25-107902.md) | [2,471 d](/filings/0001213900-26-032683.md) | [2,748](/filings/0001213900-26-054209.md) | [2,485](/filings/0001213900-26-086974.md) | [2,700](/filings/0001213900-25-107902.md) | [4,553 d](/filings/0001213900-26-032683.md) | [3,642](/filings/0001213900-26-054209.md) | [3,132](/filings/0001213900-26-086974.md) |
| Selling, general and administrative | $k | [1,426](/filings/0001213900-24-004149.md) | [1,875 d](/filings/0001213900-24-028894.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(3,385)](/filings/0001213900-24-097861.md) | [(6,723) d](/filings/0001013762-25-004299.md) | [(4,884)](/filings/0001213900-25-038468.md) | [(4,852)](/filings/0001213900-25-069663.md) | [(4,972)](/filings/0001213900-25-107902.md) | [(4,549) d](/filings/0001213900-26-032683.md) | [(5,107)](/filings/0001213900-26-054209.md) | [(5,070)](/filings/0001213900-26-086974.md) | [(5,708)](/filings/0001213900-25-107902.md) | [(6,385) d](/filings/0001213900-26-032683.md) | [(5,959)](/filings/0001213900-26-054209.md) | [(5,569)](/filings/0001213900-26-086974.md) |
| Interest expense | $k | not reported | not reported | [36.0](/filings/0001213900-25-038468.md) | [132](/filings/0001213900-25-069663.md) | [264](/filings/0001213900-25-107902.md) | [384 d](/filings/0001213900-26-032683.md) | [495](/filings/0001213900-26-054209.md) | [624](/filings/0001213900-26-086974.md) | [471](/filings/0001213900-25-107902.md) | [0.0 d](/filings/0001213900-26-032683.md) | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [1,563](/filings/0001213900-24-097861.md) | [(4,895) d](/filings/0001013762-25-004299.md) | [(6,270)](/filings/0001213900-25-107902.md) | [(3,947)](/filings/0001213900-25-107902.md) | [(5,960)](/filings/0001213900-25-107902.md) | [(4,618) d](/filings/0001213900-26-032683.md) | [(4,998)](/filings/0001213900-26-086974.md) | [(5,690)](/filings/0001213900-26-086974.md) | [(6,482)](/filings/0001213900-25-107902.md) | [(6,586) d](/filings/0001213900-26-032683.md) | [(4,351)](/filings/0001213900-26-086974.md) | [(5,982)](/filings/0001213900-26-086974.md) |
| Diluted EPS | $ per share | [0.13](/filings/0001213900-24-097861.md) | not reported | [(0.41)](/filings/0001213900-25-038468.md) | [(0.29)](/filings/0001213900-25-069663.md) | [(0.39)](/filings/0001213900-25-107902.md) | not reported | [(0.29)](/filings/0001213900-26-054209.md) | [(0.32)](/filings/0001213900-26-086974.md) | [(0.35)](/filings/0001213900-25-107902.md) | not reported | [(0.08)](/filings/0001213900-26-054209.md) | [(0.07)](/filings/0001213900-26-086974.md) |
| Basic EPS | $ per share | [0.13](/filings/0001213900-24-097861.md) | not reported | [(0.41)](/filings/0001213900-25-038468.md) | [(0.29)](/filings/0001213900-25-069663.md) | [(0.39)](/filings/0001213900-25-107902.md) | not reported | [(0.29)](/filings/0001213900-26-054209.md) | [(0.32)](/filings/0001213900-26-086974.md) | [(0.35)](/filings/0001213900-25-107902.md) | not reported | [(0.08)](/filings/0001213900-26-054209.md) | [(0.07)](/filings/0001213900-26-086974.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.4](/filings/0001213900-24-004149.md) | [4.2](/filings/0001213900-24-028894.md) | [4.9](/filings/0001213900-24-043566.md) | [1.7](/filings/0001213900-24-067381.md) | [4.4](/filings/0001213900-24-097861.md) | [5.5](/filings/0001013762-25-004299.md) | [5.3](/filings/0001213900-25-038468.md) | [5.3](/filings/0001213900-25-069663.md) | [3.6](/filings/0001213900-25-107902.md) | [3.7](/filings/0001213900-26-032683.md) | [25.3](/filings/0001213900-26-054209.md) | [19.7](/filings/0001213900-26-086974.md) |
| Current assets | $m | [20.3](/filings/0001213900-24-004149.md) | [7.5](/filings/0001013762-25-004299.md) | [7.7](/filings/0001213900-24-043566.md) | [5.0](/filings/0001213900-24-067381.md) | [7.1](/filings/0001213900-24-097861.md) | [8.9](/filings/0001213900-26-032683.md) | [8.3](/filings/0001213900-25-038468.md) | [7.5](/filings/0001213900-25-069663.md) | [5.8](/filings/0001213900-25-107902.md) | [6.3](/filings/0001213900-26-086974.md) | [27.7](/filings/0001213900-26-054209.md) | [21.9](/filings/0001213900-26-086974.md) |
| Total assets | $m | [21.2](/filings/0001213900-24-004149.md) | [8.3](/filings/0001013762-25-004299.md) | [8.5](/filings/0001213900-24-043566.md) | [6.7](/filings/0001213900-24-067381.md) | [9.4](/filings/0001213900-24-097861.md) | [11.5](/filings/0001213900-26-032683.md) | [10.4](/filings/0001213900-25-038468.md) | [9.9](/filings/0001213900-25-069663.md) | [8.2](/filings/0001213900-25-107902.md) | [8.6](/filings/0001213900-26-086974.md) | [29.8](/filings/0001213900-26-054209.md) | [23.9](/filings/0001213900-26-086974.md) |
| Current liabilities | $m | [12.7](/filings/0001213900-24-004149.md) | [7.3](/filings/0001013762-25-004299.md) | [7.0](/filings/0001213900-24-043566.md) | [8.1](/filings/0001213900-24-067381.md) | [9.1](/filings/0001213900-24-097861.md) | [7.5](/filings/0001213900-26-032683.md) | [7.6](/filings/0001213900-25-038468.md) | [8.0](/filings/0001213900-25-069663.md) | [9.0](/filings/0001213900-25-107902.md) | [11.6](/filings/0001213900-26-086974.md) | [12.2](/filings/0001213900-26-054209.md) | [12.6](/filings/0001213900-26-086974.md) |
| Total liabilities | $m | [16.4](/filings/0001213900-24-004149.md) | [10.0](/filings/0001013762-25-004299.md) | [15.9](/filings/0001213900-24-043566.md) | [19.1](/filings/0001213900-24-067381.md) | [27.9](/filings/0001213900-24-097861.md) | [30.4](/filings/0001213900-26-032683.md) | [34.6](/filings/0001213900-25-038468.md) | [39.8](/filings/0001213900-25-069663.md) | [15.7](/filings/0001213900-25-107902.md) | [20.3](/filings/0001213900-26-086974.md) | [19.3](/filings/0001213900-26-054209.md) | [20.3](/filings/0001213900-26-086974.md) |
| Shareholders' equity | $m | [4.8](/filings/0001213900-24-097861.md) | [(1.8)](/filings/0001213900-26-032683.md) | [(7.4)](/filings/0001213900-25-107902.md) | [(12.4)](/filings/0001213900-25-107902.md) | [(18.5)](/filings/0001213900-25-107902.md) | [(18.8)](/filings/0001213900-26-086974.md) | [(24.2)](/filings/0001213900-26-086974.md) | [(29.9)](/filings/0001213900-26-086974.md) | [(7.7)](/filings/0001213900-25-107902.md) | [(12.2)](/filings/0001213900-26-086974.md) | [10.2](/filings/0001213900-26-086974.md) | [3.3](/filings/0001213900-26-086974.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1.1 d](/filings/0001213900-24-097861.md) | [(11.1) d](/filings/0001013762-25-004299.md) | [(5.6)](/filings/0001213900-25-038468.md) | [(4.6) d](/filings/0001213900-25-069663.md) | [(2.6) d](/filings/0001213900-25-107902.md) | [(5.1) d](/filings/0001213900-26-032683.md) | [(3.7)](/filings/0001213900-26-054209.md) | [(4.5) d](/filings/0001213900-26-086974.md) | [(4.3) d](/filings/0001213900-25-107902.md) | [(5.7) d](/filings/0001213900-26-032683.md) | [(6.1)](/filings/0001213900-26-054209.md) | [(5.5) d](/filings/0001213900-26-086974.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001213900-24-097861.md) | [0.0 d](/filings/0001013762-25-004299.md) | [0.1](/filings/0001213900-25-038468.md) | [0.2 d](/filings/0001213900-25-069663.md) | [1.2 d](/filings/0001213900-25-107902.md) | [(0.5) d](/filings/0001213900-26-032683.md) | [0.0](/filings/0001213900-26-054209.md) | [0.0 d](/filings/0001213900-26-086974.md) | [0.0 d](/filings/0001213900-25-107902.md) | [0.2 d](/filings/0001213900-26-032683.md) | not reported | not reported |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | [0.6 d](/filings/0001213900-26-032683.md) | [1.2](/filings/0001213900-26-054209.md) | [0.6 d](/filings/0001213900-26-086974.md) | [0.0 d](/filings/0001213900-25-107902.md) | [(0.0) d](/filings/0001213900-26-032683.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.1](/filings/0001213900-24-004149.md) | [10.1](/filings/0001213900-24-043566.md) | [10.1](/filings/0001213900-24-067381.md) | [11.2](/filings/0001213900-24-097861.md) | [18.6](/filings/0001213900-25-038468.md) | [18.6](/filings/0001213900-25-069663.md) | [18.6](/filings/0001213900-25-107902.md) | [21.3](/filings/0001213900-26-054209.md) | [21.4](/filings/0001213900-26-086974.md) | [21.9](/filings/0001213900-25-107902.md) | [68.9](/filings/0001213900-26-054209.md) | [104](/filings/0001213900-26-086974.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 77,194,595 at 2026-08-10, from the cover of the [10-Q filed 2026-08-10](/filings/0001213900-26-086974.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.